45-minutes. No compromises.
Vancomycin Resistant Enterococcus (VRE) is a critical pathogen among high risk patients. Previous testing methodologies are time consuming and often require unnecessary isolation. Xpert vanA empowers clinicians to make critical decisions at time of patient admission, thereby improving the quality of patient care and reducing cost.
According to the Centers for Disease Control and Prevention (CDC), Enterococci cause about 1 of every 8 hospital infections with 30% of those infections, caused by Vancomycin-Resistant Enterococci (VRE)1. However, VRE can be even more prevalent in high risk groups, such as immunocompromized and ICU patients.
The human and financial impact of VRE is high2:
- Attributable mortality: 10%
- Extended length of stay: 6.2 days
- Incremental cost: $12,800
(1) http://www.cdc.gov/ncidod/dhqp/ar_VRE_publicFAQ.html; (2) Carmeli et al., “Health and Economic Outcomes of Vancomycin-Resistant Enterococci”. Archives of Internal Medicine 2002; 162:2223-2228.
The CDC and SHEA have both published guidelines on how to reduce or eliminate healthcare associated infections.3,4 As a part of a quality infection control program, Cepheid's Xpert vanA provides:
- Immediate detection of the vanA gene most closely associated with VRE colonization
- Superior NPV required in a surveillance test
- Easy-to-use test with less than 2 minutes hands-on-time
(3) Siegel, Jane, et al. “Management of Multidrug-Resistant Organisms In Healthcare Settings, 2007,” Center for Disease Control, 2007.; (4) Muto, Carlene, et al. “SHEA Guideline for Preventing Nosocomial Transmission of Multidrug-Resistant Strains of Staphylococcus aureus and Enterococcus”, Infect Control Hosp Epidemiol 2003; 24:362-386.
- Cepheid - The Molecular Diagnostics Leader
- Catalog #: GXVANA-10
Number of Tests: 10
- How can I place an order?
Submit your request using our Request Information form, or call 1.888.838.3222, select option 1.